Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients

Abstract

Efficacy comparison of icotinib and pemetrexed in the treatment of lung adenocarcinoma and the effects on the prognostic survival rate of patients were investigated. A retrospective analysis was performed in 132 lung adenocarcinoma patients who were treated in the Affiliated Hospital of Weifang Medical University from July 2010 to July 2015. Among them, 69 patients were treated with icotinib (icotinib group), and 63 patients were treated with pemetrexed (pemetrexed group). In the icotinib group, 125 mg icotinib was orally administered continuously, 3 times a day, until progressive disease or intolerable adverse reactions occurred. In the pemetrexed group, 500 mg/m 2 pemetrexed was intravenously dripped for a total of 4 cycles, 21 days for 1 cycle, until progressive disease or intolerable adverse reactions occurred. The efficacy, toxic and side effects, and survival rate of the two groups were evaluated. There was a statistically significant difference in toxic and side effects between the two groups of drugs after the treatment of lung adenocarcinoma (P<0.05). The median survival time of patients was 16 months in the icotinib group and 10 months in the pemetrexed group, with a statistically significant difference (P<0.05). The 1-year survival rate was higher in the icotinib group than that in the pemetrexed group (P<0.05). There was no difference in 2- and 3-year survival rates between the two groups (P>0.05). In conclusion, the clinical efficacy of icotinib is similar to that of pemetrexed in the treatment of lung adenocarcinoma, but icotinib has less adverse reactions, with better improvement in disease control.

Identification of Two Subtypes and Prognostic Characteristics of Lung Adenocarcinoma Based on Pentose Phosphate Metabolic Pathway-Related Long Non-coding RNAs

“…The most frequent lung cancer histological subtype, accounting for ~50% of all the cases, is lung adenocarcinoma (LUAD). Patients with LUAD are at a high risk of distant metastases at each stage of the disease progression ( 2 ), along with high malignancy and poor prognoses ( 3 , 4 ). Treatment of LUAD is based on grading and stage, mainly determined using the patients' characteristics and the pathological assessment of the tumor histology ( 5 ).…”

Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study

“…Lung adenocarcinoma (LUAD) is the most common type of lung cancer, accounting for nearly 50% of non-small-cell lung cancers (NSCLC) [ 3 , 4 ]. LUAD is characterized by a high degree of malignancy and poor prognosis [ 5 ]. In recent years, the incidence and mortality of LUAD have increased, despite the introduction of novel therapeutic approaches including immunotherapy or molecular targeted therapy [ 6 , 7 ].…”

Establishment of lung adenocarcinoma classification and risk model based on necroptosis-related genes

“…Its most widely known histological subtype is the Lung adenocarcinoma (LUAD), making up about 50% of the total lung cancer cases. It has a high risk of distant metastasis at each stage ( Shi et al, 2016 ) and is linked with increased malignancy and a worse prognosis ( Gong et al, 2019 ; Zhou et al, 2019 ). LUAD treatment is based on grade and stage and is mainly determined by the evaluation of tumor histology and patient characteristics by pathologists ( Wei et al, 2019 ).…”